(15 April 2020) Favipiravir- significantly improved latency to relief for pyrexia and cough

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v4

In a prospective, randomized, controlled, open-label multicenter trial involving 240 adult patients with COVID-19. Favipiravir, compared to Arbidol, did not significantly improve the clinically recovery rate at Day 7. Favipiravir significantly improved the latency to relief for pyrexia and cough. Adverse effects caused Favipiravir are mild and manageable. This trial is registered with Chictr.org.cn
(ChiCTR2000030254).